Psoriatic Arthritis | Emerging Therapies | Xeljanz (tofacitinib) | US | Wave 1 | 2018
Market Outlook
Xeljanz is the first-in-class JAK inhibitor approved for psoriatic arthritis (PsA); it is also the only other oral targeted therapy, besides Celgene’s PDE-4 inhibitor, Otezla, approved for this indication. In recent years, multiple new therapies have been approved for the treatment of PsA. However, Xeljanz’s unique MOA, oral administration, and strong efficacy warrant the attention of both rheumatologists and dermatologists.
The PsA Emerging Therapy series includes three waves that will track the awareness, trial, and usage of Xeljanz since its approval in December 2017 for the treatment of PsA. In addition, the series will examine physician-anticipated future trends in PsA treatment and in particular Xeljanz uptake, as well as assess Pfizer’s promotional efforts.
Questions Answered
- What is the awareness of, familiarity with, and perception related to Xeljanz among U.S. rheumatologists and dermatologists?
- Among prescribers, for which patients are they prescribing Xeljanz, what are the reasons for prescribing, and how satisfied are physicians with Xeljanz ?
- How do prescribers and nonprescribers compare across key metrics?
- How is the trial and adoption of Xeljanz tracking compared to other recent product launches in the autoimmune market?
Product Description
Emerging Therapies: is a three-wave series based on primary research data collected at 1, 6, and 12 months post-commercial launch with U.S. physicians. The research captures physicians’ awareness, perceptions, and usage of the launched product, as well as the impact on current therapies and anticipated future trends. Insight is also provided on promotional efforts, prescriber and nonprescriber profiles, and benchmarking against other launched agents.
